Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003552 · ClinicalTrials.gov registry record · Phase 1
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma
A Phase 1 study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00003552 is a Phase 1 study that was terminated before completion, run by National Heart, Lung, and Blood Institute (NHLBI).
The verdict
NCT00003552, a Phase 1 study, was terminated before completion, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of chemotherapy plus peripheral stem cell transplantation in treating patients with metastatic melanoma.
Interventions
- DRUG fludarabine
- DRUG cyclophosphamide
- DRUG anti-thymocyte globulin
- DRUG allogeneic lymphocytes
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-01 |
| Est. Completion | 2002-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003552
The ClinicalTrials.gov registry entry for NCT00003552 describes a study currently listed as terminated, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which fludarabine is the first listed.
NCT00003552 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003552 about?
NCT00003552 is a clinical study titled "Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy and kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of chem...
What is the current status of trial NCT00003552?
This trial is currently terminated. It is a Phase 1 study. The study started on 1999-01. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00003552?
The interventions under investigation include: fludarabine (DRUG), cyclophosphamide (DRUG), anti-thymocyte globulin (DRUG), allogeneic lymphocytes (DRUG).
Who is sponsoring clinical trial NCT00003552?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.